Calidi Biotherapeutics (CLDI) Depreciation & Amortization - Total (2024 - 2025)
Calidi Biotherapeutics' quarterly Depreciation & Amortization - Total came in at $94000.0 in Q4 2025, down 6.0% year-on-year from $100000.0 in Q4 2024, and down 10.48% quarter-over-quarter from $105000.0 in Q3 2025.
Calidi Biotherapeutics has reported Depreciation & Amortization - Total for 2 years, with the latest figure at $94000.0 in Q4 2025.
- For the quarter ending Q4 2025, Depreciation & Amortization - Total fell 6.0% year-over-year to $94000.0; the trailing twelve-month figure through Dec 2025 stood at $295000.0 (down 1.67% YoY), and the FY2025 full-year result was $386000.0, down 3.98% from the prior year.
- Depreciation & Amortization - Total for Q4 2025 stood at $94000.0, down from $105000.0 in the prior quarter.
- The five-year high for Depreciation & Amortization - Total was $105000.0 in Q3 2025, with the low at $94000.0 in Q4 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Dep. & Amort. (Tot) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,638,563.89 Bn | 1,638,563.89 Bn | - | - |
| 2 | Alterity Therapeutics | 767,934.24 Bn | 767,934.20 Bn | - | - |
| 3 | Legend Biotech | 2,937.00 Bn | 2,936.10 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,282.79 Bn | 2,282.72 Bn | - | - |
| 5 | Akari Therapeutics | 2,169.69 Bn | 2,169.69 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 110.41 Bn | 103.16 Bn | 2.59 Bn | - |
| 7 | Regeneron Pharmaceuticals | 66.44 Bn | 57.69 Bn | 3.31 Bn | - |
| 8 | Evaxion A | 65.44 Bn | 65.42 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.53 Bn | 36.52 Bn | 959.66 Mn | - |
| 10 | Calidi Biotherapeutics | - | - | - | 94,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 94,000.00 |
| Sep 30, 2025 | 105,000.00 |
| Jun 30, 2025 | 96,000.00 |
| Dec 31, 2024 | 100,000.00 |
| Sep 30, 2024 | 99,000.00 |
| Jun 30, 2024 | 101,000.00 |